Recruiting at 1 site Phase 3 Obesity, Childhood

Obesity, Childhood study: Metformin

Official title Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance

ClinicalTrials.gov ID: NCT04578652

What this study is testing

What is Metformin 850 mg oral tablet bid?

Metformin 850 mg oral tablet bid is an investigational medicine, taken by mouth once daily, being studied as a potential treatment for obesity, childhood.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The study wants to see if adding fiber to metformin works better than either alone at improving insulin resistance, lowering BMI, and reducing inflammation. It also looks at how the gut bacteria change.
Who it's for
Teenagers who are obese, have insulin resistance, and a family history of type 2 diabetes.
What's involved
Participants will be randomly assigned to take fiber, metformin, or both for a year, with regular clinic visits and blood tests to check glucose, weight, inflammation, and gut microbes.
Time commitment
The trial lasts 12 months with multiple scheduled visits for medication dispensing and testing.
  • Phase 3: a large, late-stage study
  • Time commitment: about 12 months
  • Which group you join is decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 12 to 18

You may be able to join if

  • Age 12-18 years
  • BMI percentile \> 95% for age/sex;
  • Total weight fluctuation over past 6 months \< 10%;
  • HOMA-IR \> 3.16;
  • FH of T2DM (first or second-degree relative).

You likely can't join if

  • Current use of insulin or diagnosis of T2DM;
  • Systolic or diastolic blood pressure (BP) \> 99th percentile for age and sex;
  • Acute infectious or inflammatory condition over the preceding 1 month; hospitalization \> 48 hrs;
  • History of chronic disease such as inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders;
  • Active malignancy;
  • Concomitant use of medication/investigational drug known to affect body weight in the past year;
See the full eligibility criteria
Who can join
  • Age 12-18 years
  • BMI percentile \> 95% for age/sex;
  • Total weight fluctuation over past 6 months \< 10%;
  • HOMA-IR \> 3.16;
  • FH of T2DM (first or second-degree relative).
What rules you out
  • Current use of insulin or diagnosis of T2DM;
  • Systolic or diastolic blood pressure (BP) \> 99th percentile for age and sex;
  • Acute infectious or inflammatory condition over the preceding 1 month; hospitalization \> 48 hrs;
  • History of chronic disease such as inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders;
  • Active malignancy;
  • Concomitant use of medication/investigational drug known to affect body weight in the past year;
  • Antibiotic use in past 60 days; probiotic and/or prebiotic supplements use in the past 30 days; use of lipid-lowering and anti-inflammatory medication.

The study team makes the final eligibility decision.

Where it is enrolling

  • Edmonton, Alberta, Canada

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The study runs about 12 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.

Who can join this trial?

This study is enrolling all sexes, 12 years to 18 years. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Edmonton, Alberta, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.